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Toxicogenomics, an emerging ﬁeld in molecu-
lar toxicology, offers the promise of new
approaches to identify and characterize such
factors as the biologic activity of new and
existing chemicals and drugs and could play
an important role in hazard assessment for
human health. This revolutionary field can
potentially affect many scientiﬁc and medical
areas, including the development of a new
generation of alternative predictive testing and
screening methods that could lend themselves
to the reduction, reﬁnement, and replacement
of animals used for such purposes.
The European Centre for the Validation 
of Alternative Methods (ECVAM), the 
U.S. Interagency Coordinating Committee 
on the Validation of Alternative Methods
(ICCVAM), and the National Toxicology
Program Interagency Center for the Evaluation
of Alternative Toxicological Methods
(NICEATM) are currently investigating the
speciﬁc considerations necessary for adequate
validation of toxicogenomics-based test meth-
ods. The primary objective of ECVAM and
ICCVAM/NICEATM is to facilitate develop-
ment, validation, and regulatory acceptance of
new, revised, and alternative test methods that
reduce, reﬁne, and replace the use of animals
(referred to as the three Rs; Russell and Burch
1959) in testing while maintaining and pro-
moting scientiﬁc quality and the protection of
human health, animal health, and the environ-
ment. The efforts of such organizations as
ICCVAM/NICEATM and ECVAM have
helped foster the principles of the three R’s and
have contributed to progress in the use of alter-
native methods for regulatory, research, and
educational purposes.
Experience in the validation of conventional
alternative test methods has led to an under-
standing that new and innovative approaches
likely will be necessary to standardize test
methods based on toxicogenomics and to
evaluate the scientiﬁc validity and regulatory
applicability of such test methods. It is envi-
sioned that the entire validation process will be
more complex and challenging than that typi-
cally encountered thus far for other alternative
test methods. This is because not only will the
technology itself need to be standardized and
validated, but the methods that are based upon
the technology and their predictive aspects will
also need to undergo validation if they are to
be employed in regulatory decision-making
processes. In addition the validation process
must be able to accommodate the anticipated
rapid changes in technology that could affect
the performance of the test method and its
reliability for a speciﬁc purpose.
Toxicogenomics-based methods are being
widely applied in toxicology and biomedical
research. Because data are already being gener-
ated using these technologies, it is both timely
and important to address the subject of valida-
tion now with the aim of establishing a
foundation that will facilitate future regula-
tory acceptance of scientifically validated
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This is the report of the ﬁrst workshop “Validation of Toxicogenomics-Based Test Systems” held
11–12 December 2003 in Ispra, Italy. The workshop was hosted by the European Centre for the
Validation of Alternative Methods (ECVAM) and organized jointly by ECVAM, the U.S. Interagency
Coordinating Committee on the Validation of Alternative Methods (ICCVAM), and the National
Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological
Methods (NICEATM). The primary aim of the workshop was for participants to discuss and deﬁne
principles applicable to the validation of toxicogenomics platforms as well as validation of speciﬁc tox-
icologic test methods that incorporate toxicogenomics technologies. The workshop was viewed as an
opportunity for initiating a dialogue between technologic experts, regulators, and the principal valida-
tion bodies and for identifying those factors to which the validation process would be applicable. It
was felt that to do so now, as the technology is evolving and associated challenges are identiﬁed,
would be a basis for the future validation of the technology when it reaches the appropriate stage.
Because of the complexity of the issue, different aspects of the validation of toxicogenomics-based test
methods were covered. The three focus areas include a) biologic validation of toxicogenomics-based
test methods for regulatory decision making, b) technical and bioinformatics aspects related to valida-
tion, and c) validation issues as they relate to regulatory acceptance and use of toxicogenomics-based
test methods. In this report we summarize the discussions and describe in detail the recommendations
for future direction and priorities. Key words: acceptance, alternatives, biomarker, predictive test, regu-
latory use, standardization, toxicogenomics, toxicology, validation. Environ Health Perspect
114:420–429 (2006). doi:10.1289/ehp.8247 available via http://dx.doi.org/ [Online 17 August 2005]toxicogenomics-based test methods. By
addressing the critical validation issues early,
and in parallel with the evolutionary and matu-
ration phases of the technologic development
of toxicogenomics-based methods, it should be
possible to preempt many potential pitfalls and
data gaps encountered with retrospective
method evaluations that could impede valida-
tion of this promising research and regulatory
tool. Such a strategy will also facilitate early
buy-in and conﬁdence in the technologies by
the regulatory arena in its quest for new,
improved, and relevant methods by which to
help ensure human health, protect the environ-
ment, and demonstrate responsiveness to
animal welfare issues.
In consideration of all these related issues,
ECVAM and ICCVAM/NICEATM held the
ﬁrst of a planned series of workshops to address
the validation principles that lend themselves to
toxicogenomics-based test methods, for exam-
ple, gene expression technologies and associated
bioinformatics. Given the complexity of the
rapidly evolving toxicogenomics ﬁeld, a variety
of issues were addressed. These included but
were not limited to a) differences in and evolu-
tion of technology platforms including changes
in genome coverage for model species; b) qual-
ity assurance (QA) and Good Laboratory
Practice (GLP) compliance; c) technology stan-
dardization, transferability, and reproducibility;
d) relevance to in vivo biological responses;
e) yardsticks against which toxicogenomics
responses should be measured; f) data evalua-
tion, statistical approaches, and databases;
g) validation approaches; and h) regulatory
acceptability.
To begin to examine these complex issues,
three breakout groups were formed. Each
group concentrated on different aspects of the
validation of toxicogenomics-based test meth-
ods, and the discussions were shared with the
other participants in plenary sessions. The
three focus areas were a) biological validation
of toxicogenomics-based test methods for
regulatory decision making, b) technical and
bioinformatics aspects related to validation,
and c) validation issues as they relate to regula-
tory acceptance and use of toxicogenomics-
based test methods.
Validation of Toxicogenomics:
Focus on the Biological
Systems
The biological issues related to the validation of
toxicogenomics-based test methods involved
two strategies proposed for developing and vali-
dating such methods so that they can be
employed to support regulatory decision mak-
ing. One strategy involves phenotypic anchor-
ing of gene expression changes to identify
molecular mechanisms and candidate bio-
markers of toxicity (i.e., single genes, proteins,
or biological pathways). A second strategy
involves the identification and validation of
predictive gene expression signatures of toxi-
city. Validation considerations speciﬁc to data
quality and cross-platform and interlaboratory
variability that are common to both strategies
were identified. It is acknowledged that any
new toxicogenomics-based methods will need
to address established validation criteria for
determination of reliability and relevance (Balls
et al. 1995; ICCVAM 1997, 2003) as well as
articulate the advantages and limitations of a
given toxicogenomics-based test method. In
addition biological validation of such a test
method, that is, assessment of the concordance
of gene changes with biological events, is essen-
tial but is contingent upon validation of the
technology itself, which is addressed elsewhere
in this article.
Strategy 1: use of toxicogenomics data to
define mechanism and identify biomarkers.
Toxicogenomics offers the opportunity to
enhance existing toxicity prediction strategies
through elucidation of biological mechanisms
around critical events. This sentiment is cap-
tured in the recent U.S. Environment Protec-
tion Agency (EPA) and U.S. Food and Drug
Administration (FDA) strategies regarding the
inclusion of genomics data in submissions of
regulated substances (U.S. EPA 2002; U.S.
FDA 2005). Although these agencies currently
preclude basing regulatory decision making on
genomics data alone, they do encourage the
voluntary submission of well-documented,
quality genomics data. Both agencies are con-
sidering the use of submitted data on a case-by-
case basis for assessment purposes (e.g., to help
elucidate mechanism of action or contribute to
a weight-of-evidence approach) or for populat-
ing relevant comparative databases by encour-
aging parallel submissions of genomics data
and traditional toxicologic test results. This
approach is appropriate given the state of scien-
tific knowledge of toxicogenomics and the
requisite need for a clear understanding of the
toxicologic relevance of the gene expression sig-
nals detected by this technology. There is a
small but rapidly increasing number of pub-
lished reports demonstrating a linkage between
gene expression changes and adverse pheno-
typic changes (Huang et al. 2003; Orphanides
2003). These reports provide qualitative evi-
dence of the power of genomics to link pheno-
type with gene expression, thereby contributing
to an understanding of mechanism of action.
Some such reports demonstrate the predictive
power of these data to classify compounds.
However, they fail to address adequately quan-
titative dose- and time-dependent (e.g., thresh-
old) responses that are the hallmark of
toxicologic evaluation, making their immediate
acceptance in regulatory arenas circumspect.
Nonetheless, toxicogenomics data may
eventually be useful in hazard and risk
assessment if data quality and validity can be
adequately substantiated. Some regulators are
finding that these data have the potential to
add to the body of knowledge about com-
pound mechanism of action. With appropriate
dose- and time-dependent measurements, gene
and protein changes can be used to mark the
molecular events that occur as an organism
moves through the continuum from exposure
to response. The obvious beneﬁt is the identiﬁ-
cation of early markers of response, including
responses that mark the point of departure
from adaptation to toxicity. In addition, it may
be possible to detect unforeseen effects at very
low doses or in unexpected tissues (Brown
et al. 2002). This is important because changes
in gene or protein expression alone are not suf-
ficient to differentiate toxicity from biologic
adaptation after exposure to an exogenous
compound. The challenge for predictive toxi-
cology is to link changes in gene and protein
expression to sequential changes in phenotype,
both adaptive and adverse, in a manner that is
consistent with the underlying biologic mecha-
nisms. For example, gene expression proﬁling
has been used to classify hepatotoxins based on
mechanism of action and to differentiate early,
presumably adaptive, responses from later
responses that are reflective of toxicity
(Hamadeh et al. 2002a, 2002b; Waring et al.
2001, 2003). The gene expression changes cor-
related well with changes in histopathology
and clinical chemistry, supporting the liver as
target organ for the test compounds.
Although good technical progress has
been made in recent years, additional proof-
of-principle studies are needed for the regula-
tory community to become more accepting of
the use of toxicogenomics data as part of the
regulatory decision-making process. It would
be important to demonstrate, for instance,
that toxicogenomics not only can confirm
what is already known about specific com-
pounds and toxic end points (i.e., phenotypic
anchoring) but also can accurately predict
toxicity for unknown compounds. The task is
to present regulatory scientists with new
knowledge gained from toxicogenomics
approaches in a familiar context. Ideally, at
least in the short term, the focus will be the
identiﬁcation of single, or small sets of, genes
or proteins that serve as biomarkers of
response, as opposed to signatures of response
that are the typical output of microarray
experiments. Simple biomarkers of response
are favored over complex expression signa-
tures because they are familiar in toxicology
assessment, are easy to maintain over time
(e.g., are independent of the microarray plat-
form), and can be readily validated.
Validation strategies for toxicogenomics-
based markers can be modeled after protocols
for existing biomarkers. Thus, global gene
expression technologies such as microarrays
can be used to identify a speciﬁc gene marker,
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dated by conventional methods such as
Northern blot analysis, in situ hybridization,
and quantitative polymerase chain reaction.
This approach has advantages because regula-
tory agencies such as the U.S. FDA have pro-
posed procedures to address gene and protein
biomarkers, and other organizations, such as
the Organisation for Economic Co-operation
and Development (OECD 2005), are
embarking on establishing similar guidance
(Supplemental Material, Section 1; http://
ehp.niehs.nih.gov/members/2005/8247/
suppl.pdf).
Proof-of-principle studies could be con-
ducted concurrently with existing regulatory
test methods using similar samples of test com-
pounds. In such situations, it may be appropri-
ate to use in vivo systems, which are widely
accepted by the regulatory community. Parallel
in vitro studies could be conducted in situations
where an appropriate test system is available. It
may be wise to focus initial efforts on deﬁning
relationships between gene expression changes
and toxicity for individual compounds or com-
pound classes with well-defined end points.
The experimental design should address con-
ventional aspects of dose and time (dose
response), species and strain susceptibility,
group size and sex, and selection of end points
for study (e.g., histopathology, clinical chem-
istry). Numerous commercial microarray plat-
forms offer genomewide coverage for model
systems such as rat, mouse, Caenorhabditis
elegans, and humans. Commercial microarrays
are also available for genes that are highly
expressed in speciﬁc tissues (e.g., liver, breast)
and during speciﬁc biological processes such as
metabolism (e.g., P450 enzymes). Both
genomewide and dedicated arrays can be used
with RNA samples from in vivo and in vitro
(tissue and cell culture) systems, enabling paral-
lel studies to be conducted with a single
microarray platform. This is important because
the results of microarray experiments can vary
depending on the array design and the selection
and performance of gene probes on the array.
Encouraging results on cross-platform compar-
isons and between-laboratory reproducibility
are now emerging (Bammler et al. 2005; Chu
et al. 2004; Irizarry et al. 2005; Larkin et al.
2005; Yauk et al. 2004). Toxicogenomics stud-
ies conducted in parallel and comparative sys-
tems can demonstrate the biologic relevance of
in vitro models as surrogates for in vivo models
without the need to address cross-platform
(technologic) issues (Boess et al. 2003; Huang
et al. 2003). Although initial efforts should
focus on deﬁning simple gene and protein bio-
markers for specific compound classes, end
points, and model systems, the end goal is to
establish a compendium of compound-speciﬁc
knowledge that transcends technology plat-
form. Ideally, the markers should be robust
enough to withstand technologic advances in
toxicology that add to the existing knowledge
about the compound. Once sufﬁcient and ade-
quately validated data are available, toxico-
genomics can become part of a hierarchical
approach to compound assessment.
The use of toxicogenomics to identify
(screen) compounds with the potential to
cause adverse effects may present opportuni-
ties to reduce the need for full animal tests, or
perhaps reﬁne animal use, and/or reduce the
numbers of animals needed when in vivo tests
are necessary. Of course, the statistical power
of any test will inﬂuence the number of ani-
mals used in an in vivo test as well. Screening-
type assessments may be appropriate for
priority setting, dose setting, chemical rank-
ing, and so forth. The extent of validation
required for screening tests may be different
than that required for full replacement tests
because negative compounds might still
undergo full animal testing. Establishing a
compendium of compound-speciﬁc informa-
tion will enable regulators and sponsors to
access what is known about a compound
across multiple test systems, species, and end
points, thereby improving the biological rele-
vance of regulatory decisions to safeguard
human health and the environment.
Strategy 2: use of gene expression signatures
to predict toxicity. Toxicogenomics holds great
promise for improving predictive toxicologic
assessments. Gene expression profiling has
been used to classify compounds by chemical
class and mechanism (Hughes et al. 2000;
Scherf et al. 2000; Steiner et al 2004; Thomas
et al. 2001), tumors by origin and type (Chung
et al. 2002), and breast cancer patients for fol-
low-up chemotherapy (van ‘t Veer et al. 2002).
In all cases, classiﬁcation was based on a set of
discriminatory gene elements, between 10 and
several hundred, identiﬁed from a larger pool
of genes on a microarray. The pattern of gene
expression, not the measurement of a single or
a small set of genes, was the basis for classiﬁca-
tion. A variety of gene expression analysis algo-
rithms were used to discriminate samples based
on gene expression signature. In all cases, the
compound class or tumor status was known
a priori, and gene expression signatures for
known samples were used to predict classiﬁca-
tion for other known but blinded samples
(Blower et al. 2002; Brindle et al. 2002). Such
models are currently being developed in the
private sector (e.g., Gene Logic, Iconix) and are
commercially available but cannot, as yet, be
exploited by regulators and the scientiﬁc com-
munity because the underlying data sets and
algorithms have not been made available
outside the private sector.
Predictive model development will require
an extensive “training” set of gene expression
measurements for classes of model compounds
in a variety of test systems, both in vivo and
in vitro, at multiple doses and time points.
Initial studies can be conducted concurrently
with conventional testing systems as a way to
conﬁrm model predictions. In the short term,
it is unlikely that sufﬁcient data will be avail-
able for gene expression signatures to replace
conventional approaches. Until then, such data
can be used as part of a hierarchical approach
to toxicity testing in conjunction with accepted
methods routinely used for regulatory pur-
poses. In the long-term, sufﬁcient data should
accumulate from well-designed validation stud-
ies such that gene expression signatures could
be part of a battery of tests that reduce or
replace animal procedures.
Model validation will necessitate multiple
independent data sets and application of
sophisticated statistical approaches. Acceptance
of these models will require that research and
regulatory communities have access to the data
analysis tools used to build the models, and
that they become familiar with the limitations
and uncertainties of using these complex com-
putational models. Conﬁdence in and accep-
tance of these models will also require rigorous
performance standards and appropriate con-
trols to ensure reproducibility and stability 
over time (see below) and adequate sensitivity
and speciﬁcity to discriminate toxic from non-
toxic responses. Initial model development
could easily be accelerated through coordinated 
sector-spanning efforts. Coordinated efforts
across academia, government, and industry
partnerships will accelerate progress in deﬁning
gene sets that are robust and discriminatory
both within and across technology platforms.
This is an ideal scenario given the rapidly
advancing pace of technology development.
An important aspect of any toxico-
genomics validation strategy is the need to
measure the range of biological variability of
gene responses for a given test system. Ideally,
this should be accomplished by one species,
tissue, and end point at a time, in order to
adequately assess cross-species differences that
often hamper risk assessments. Measurements
of biologic variability under baseline and toxi-
cant-challenged conditions will enable regula-
tors to better discriminate biologically relevant
responses from baseline homeostatic ﬂuctua-
tion. This is an important issue for toxicoge-
nomics, as studies conducted on cell culture
populations demonstrate a wide range of bio-
logical variability in gene expression measure-
ments for individual cells under both baseline
and challenged conditions (Kuang et al.
2004). Therefore, it is necessary to deﬁne cri-
teria to adequately address biological variabil-
ity in a data submission and to establish
whether the burden of maintaining these data
is that of the regulator or sponsor.
The recommendations related to the bio-
logical validation of toxicogenomics-based test
methods are listed in Table 1.
Corvi et al.
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Toxicogenomics-Based Methods:
Focus on the Technology
Considerations given to validation of the
technology encompassed the technical and
bioinformatics issues related to the validation
of toxicogenomics-based test methods. The
starting premise adopted was that with the
availability of bioinformatics expertise, bio-
logical data generated from toxicogenomics
studies could be interpreted with a high degree
of conﬁdence. The ultimate aim was to iden-
tify a strategic approach that would enable
credible biological observations and conse-
quential judicious regulatory decisions, and
that this approach would be independent of
the toxicogenomic platform used. Moreover,
standardization and validation of toxicoge-
nomic platforms were seen as essential for
identifying and reducing technologic artifacts.
Standardization would also be required to
increase the certainty by which biological
observations could be extrapolated across and
between different microarray platforms. It is
therefore important to build on the learning
of previous and ongoing efforts in standard-
ization of toxicogenomics (reviewed by
Sansone et al. 2004).
Three distinct levels where validation is
necessary were identiﬁed (see Figure 1 and dis-
cussion below). The ﬁrst level of validation is
the responsibility of the array manufacturer or
provider and has to be performed only once.
This can be seen as a “one-off validation” and
relates to both the microarray quality and the
instrumentation. The second level of validation
is the responsibility of both the experimental
toxicologist and the array manufacturer or
provider. This can be seen as “routine valida-
tion” or best practice to allow data comparabil-
ity. It encompasses quality control (QC)
aspects of the critical experimental components
and is a process that occurs on a regularly
scheduled basis. The third level of validation,
that is, determination of reliability and rele-
vance, is needed every time a change is intro-
duced into the test procedure. Performance
standards developed based upon the original
test method would serve as the criteria against
which the revised method would be compared.
Despite these multilevel validation needs, it
was repeatedly emphasized that significant
technologic development and progress in
microarray platforms are still under way and
that efforts to validate and standardize these
technologic platforms must not be at the
expense of innovation.
One-Off Validation
The one-off validation is the responsibility of
the array manufacturer or array provider. This
is required to ensure that the array platform
being used is robust and that the inherent vari-
ability within the platform is transparent to the
user and the regulator (Figure 1). The follow-
ing were identified as being necessary for
microarray-based toxicogenomics to be used in
regulatory assessments:
• Microarrays should be fabricated in accor-
dance with the principles of Good Manu-
facturing Practice (GMP).
• Specifications and performance criteria for
all instrumentation and method compo-
nents should be available.
•All quality assurance/quality control
(QA/QC) procedures should be transparent,
consistent, comparable, and reported.
• The array should have undergone sequence
verification, and the sequences should be
publicly available.
• All data should be exportable in a MAGE
(MicroArray and Gene Expression)-compatible
format.
Routine Validation
Routine validation is an ongoing process that is
the responsibility of the experimental toxicolo-
gist and the array manufacturer or provider
(Rockett and Hellmann 2004). Again, for
microarray-based toxicogenomic assays to be
used in regulatory decision making the follow-
ing important factors were identiﬁed (Figure 1):
• Oligos, cDNAs, or clones that are arrayed
should be randomly sequence-verified to
ensure that no errors are introduced between
batch syntheses. This verification process
should be recorded and reported by the
manufacturer
• All reagent components should be identiﬁed.
Reagents should be prepared according to
GMP and/or GLP as appropriate. Data
regarding batch variability should also be
recorded and reported
• Common reference RNA standards (house-
keeping genes) should be adopted to facilitate
comparison between array platforms. This
may be achieved in collaboration with the
international Microarray Gene Expression
Data (MGED) Society and other related
efforts (see below).
Biological standards. Performance stan-
dards, test component standards, and QC
measures are key components of any validation
strategy for a toxicologic test method.
Establishing standards is particularly important
for gene expression technologies due to the
inherent technologic and biological “noise” in
these systems. Commonly used biological stan-
dards are reference RNAs that are competi-
tively hybridized with the sample of interest in
two-channel array formats, and in vitro RNA
transcripts that are “spiked into” RNA samples
of interest in either one-channel or two-chan-
nel array formats. Establishing accepted RNA
standards will address concerns of regulatory
reviewers about data quality and variability
within and between laboratories and across dif-
ferent technology platforms. The standards will
also provide a common benchmark for regula-
tors to assess platform performance over time.
To achieve this goal, we must establish stan-
dards that maintain a deﬁned level of accuracy,
sensitivity, specificity, and reproducibility
across platforms.
Reference RNAs can be derived from tissue
extracts, cell lines, or both and serve a variety of
purposes. Workshops sponsored by govern-
ments and industry have focused on deﬁning
the speciﬁcations for reference RNAs for clini-
cal and regulatory applications (Joseph 2004).
The consensus is a that multiple RNA stan-
dards are needed to measure the accuracy,
dynamic range, sensitivity, and specificity of
varied technology platforms under varied con-
ditions. Important questions are whether regu-
latory agencies will deﬁne preferred sources of
RNA standards, and, if so, who will generate
and maintain baseline information about these
Validation of toxicogenomics-based test systems
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Table 1. Recommendations: focus on biological systems.
• Encourage increased use of toxicogenomics-based approaches to deﬁne the mechanistic context of toxic 
responses to exogenous compounds
• Promote greater understanding of the relationships between gene expression responses and altered phenotype, 
considering the biological pathways affected, dose response, and the point of departure from adaptive to toxic 
response
• Favor the identiﬁcation of biomarkers that are independent of technology platform but acknowledge the potential
strengths of pathway analysis
• Characterize the range and extent of biological variability of responses for the test systems (e.g., diurnal effects,
animal care and use, age-related context)
• Encourage the immediate use of toxicogenomics-based approaches in conjunction with conventional toxicity
testing approaches
• Explore the extent to which toxicogenomics can address cross-species responses and speciﬁc disease states
• Promote the conduct of parallel and comparative in vivo and in vitro studies to identify in vitro systems that can 
serve as surrogates for in vivo systems
• Characterize predictive toxicology models with respect to parameters such as dose, time, study design, relevance;
characterize the system to fulﬁll validation criteria
• Promote the identiﬁcation of gene and protein biomarkers as early (prognostic) markers as a reﬁnement to existing
toxicity testing methods
• Establish a compendium of toxicant information based on gene expression responses for model compounds across
multiple species, end points, and test systems
• Foster the development of effective partnerships between academic, government, and industry groups to promote
collaborative efforts to validate toxicogenomics-based test methods and generate sufﬁcient high-quality data to
support regulatory decision makingstandards. Although the selection of a given
RNA standard depends primarily on the pur-
pose and application, all RNA standards should
be tested for a clearly deﬁned number of copies
of a given sequence within an RNA preparation
over some linear range (Cronin et al. 2004).
Some initiatives are raising awareness of
the effects of variables that might hamper data
comparability and are working toward devel-
oping best practice guidelines for microarray-
based measurements (Hopkins et al. 2004).
For example, recommendations for best prac-
tice in array normalization, together with per-
formance characteristics in terms of sensitivity,
accuracy, and comparability of different array
platforms (cDNA and oligo, spotted and
in situ synthesis), are beginning to emerge
together with proposals for transparency and
availability through publicly accessible data-
bases (http://www.vam.org.uk). Other initia-
tives are considering the use of quality metrics
for standardizing and validating array-based
toxicogenomics measurements. The extent to
which such efforts will be pursued and the
impact they will have upon the standardiza-
tion issues that are a necessary prerequisite to
the validation exercises remain to be seen.
Quality assurance and Good Laboratory
Practice. GLP is intended to promote proper
documentation, quality, and authenticity of
toxicity test data and is required for data
acceptance by regulatory agencies (e.g., U.S.
FDA, U.S. EPA). At the international level,
GLP has been promulgated under the OECD
guidelines program (OECD 1998). As part of
the progression toward regulatory acceptance,
toxicogenomics experiments should ideally be
conducted in accordance with GLP. However,
at present, most large-scale toxicogenomics
efforts are not arising from GLP-compliant
laboratories, and requiring compliance for
data submission could greatly hamper the
technical advancement of new technologies
and retard their migration into the regulatory
arena. To avoid discouraging technologic
progress while maintaining a level of GLP
conformity, it could be argued that for
research and technical development and
improvement purposes, it might be acceptable
if array-based studies could at least measure up
to the reporting standards required by GLP.
However, with the adoption of the toxico-
genomics-based technologies into regulatory
decision-making practices, GLP compliance
undoubtedly will be expected. Procedural
aspects of GLP compliance not currently cap-
tured in MIAME-Tox (minimum information
about a microarray experiment for toxico-
genomics) will need to be identified but can
be incorporated over time. Until then, it may
be possible to allow for proof-of-principle and
prevalidation studies to be conducted in accor-
dance with the “intent” of GLP practices by
requiring submitters to adequately document
procedures and control measures and make
experimental data open to regulatory review.
“Best practices” for toxicogenomics can be
established until formal procedures are
adopted. This may be a more realistic solution
that permits the advancement of science while
addressing the need for QA and QC.
Validation as a Result 
of Procedural Changes
This third level of validation is necessary when-
ever a technical or methodologic change is
introduced into the test. Such changes might,
on one hand, be restricted to the microarray
technology (e.g., modiﬁcation or addition of
sequences to a microarray, changes in data
analysis procedures). Alternatively, they could
involve the experimental design (e.g., dose,
time, cell culture procedures). One considera-
tion is that a distinction between minor and
major procedural changes that might be incor-
porated into a test would help determine 
the extent of such validation necessary.
Additionally, to facilitate the process, perfor-
mance standards should be deﬁned based upon
the original validated test procedure. Minor
changes would entail a demonstration of
equivalence of results obtained with the modi-
fied test to that obtained from the validated
test. Major changes would involve the need 
to deﬁne a new set of reference materials to be
tested and a more extensive validation.
Guidance on the use of performance standards
and the elements comprising them have been
published (ICCVAM 2003) and have been
employed for in vitro dermal corrosion assess-
ment methods (ICCVAM 2004). Such guid-
ance can also help facilitate the establishment
performance standards for toxicogenomics-
based test methods in which procedural modi-
ﬁcations have been introduced after an initial
validation exercise, thereby providing a basis
for the comparison of reliability and accuracy
of the modified method relative to the vali-
dated and accepted reference test method.
The concept of performance standards was
originally developed to evaluate the acceptabil-
ity (accuracy and reliability) of proposed test
methods that are based on similar scientific
principles and that measure or predict the same
biologic or toxic effect as an accepted (previ-
ously validated) test method. Because some
regulatory authorities and international test
guidelines programs (e.g., OECD) have restric-
tions regarding the use of proprietary test
methods (methods that are copyrighted, trade-
marked, or patented), performance standards
also allow for the development and validation
of comparable nonproprietary methods based
on performance standards derived from the
corresponding proprietary antecedent method.
Under these circumstances, performance stan-
dards allow the characteristics and functional
attributes of a proprietary method or technique
to be described and offer a procedure for evalu-
ating the performance of methods claimed
to be substantially similar. A method that
meets the established performance standards is
Corvi et al.
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Figure 1. Scheme of the different steps in a toxicogenomics-based test. Three distinct levels were identiﬁed
where validation is necessary: one-off validation (left), which should be performed once and is mainly
related with the quality of the microarray and the instrumentation (blue); routine validation and QC (top),
representing the ongoing requirements that are the responsibilities of the experimental toxicologist and the
manufacturer (red); and the extent of validation necessary whenever a technical or methodologic change is
introduced in the test (right): a method should meet the preestablished performance standards in order to






















































































QC RNAconsidered sufﬁciently accurate and reliable for
the specific testing purpose for which it is
designed and is viewed as comparable with the
original test method upon which it is based. If
the correct performance standards have been
developed, a method for which the results have
the same accuracy and reliability as the original
should by deﬁnition also be as relevant as the
original method.
The conceptual framework and scope of
performance standards could be expanded or
adapted to include innovations or advance-
ments in areas such as microarray or protein or
metabolite separation and identiﬁcation tech-
nology, where proposed improvements might
or might not be generally or completely analo-
gous to those in existing systems but would still
enable similar applications. Performance stan-
dards could still provide a gauge for evaluating
newer or revised technologies to ensure that
their reliability and accuracy were at least com-
parable with that of existing acceptable tech-
niques using similar chemicals even if essential
test method components (i.e., structural, func-
tional, and procedural elements of a validated
test method to which a proposed, mechanisti-
cally and functionally similar test method
should adhere) were not substantially similar.
This level of validation, which does not
imply that a test needs to be completely revali-
dated, is of extreme importance for tests based
on rapidly evolving technologies. It would be a
mistake to immobilize these technologies by
enforcement of a strict and inﬂexible validation
approach that would hamper progress and test
improvement. Finally, a periodic reassessment
of a test method’s performance (accuracy and
reliability) employing established performance
standards would help ensure adherence to
essential test method components and the reli-
ability and accuracy of the modified test
method relative to the validated antecedent
method (Hartung et al. 2004). Such assurance
could be best established and reported by inter-
national validation bodies such as ECVAM
and ICCVAM/NICEATM, which could track
the history, performance, and validation status
of a given test.
Data Management
The lack of robust QC procedures and
capture of adequate metadata has caused prob-
lems with the analysis and reproducibility of
array-based transcriptomics investigations.
Consequently, the international MGED
Society proposed standards for publication
(Nature 2002) that were designed to clarify
the MIAME guidelines (Brazma et al. 2001).
As a result, a number of journals now require
that articles containing microarray experi-
ments must be compliant with the MIAME
standard; some also require that the data inte-
gral to the article’s conclusions be submitted
to the ArrayExpress database at the EBI
(European Bioinformatics Institute) (Brazma
et al. 2003), GEO (Gene Expression
Omnibus) at NCBI (National Center for
Biotechnology Information) (Edgar et al.
2002), and CIBEX (Center for Information
Biology Gene Expression database) at DDBJ
(DNA Databank of Japan) (Ikeo et al.
2003)—the European, American, and
Japanese database counterparts, respectively.
There is a critical need for public toxico-
genomics databases because of the signiﬁcant
volume of data associated with these experi-
ments, the complexity of comparing different
gene annotations and splice variants across plat-
forms, and the need for a resource for complex
informatics analyses of the traditional toxicol-
ogy and microarray data in parallel. However,
to fully achieve the potential of this emerging
interdisciplinary field, it is necessary that we
move toward the establishment of a common
public infrastructure for exchanging toxico-
genomics data (Mattes et al. 2004). The infra-
structure should address a) the technical
problems involved in data upload, b) the
demand for standardizing data models and
exchange formats, c) the requirement for identi-
fying minimal descriptors to represent the
experiment, d) the necessity of deﬁning param-
eters that assess and record data quality, and
e) the challenge of creating standardized
nomenclature and ontologies to describe bio-
logical data. The goal is also to create an inter-
nationally compatible informatics platform
integrating toxicology/pathology data with
transcriptomics, providing the scientiﬁc com-
munity with easy access to integrated data in a
structured standard format, facilitating data
analysis and data comparison, and enhancing
the impact of the individual data sets and the
comprehension of the molecular basis of actions
of drugs or toxicants. Ultimately, such a knowl-
edge-base could be maintained (respecting con-
fidentiality as appropriate) as a reference for
regulatory organizations to evaluate toxico-
genomics and pharmacogenomics data submit-
ted by registrants to those organizations.
The potential exists for the international
development of this public infrastructure. As
part of the collaborative undertaking with the
International Life Sciences Institute Health and
Environmental Sciences Institute (ILSI–HESI)
Technical Committee on the Application of
Genomics to Mechanism Based Risk
Assessment (http://www.hesiglobal.org/com-
mittees), the European Molecular Biology
Laboratory of the European Bioinformatics
Institute (EMBL–EBI; Brazma et al. 2003;
http://www.ebi.ac.uk/microarray/Projects/tox-
nutri/index.html), the National Institutes of
Health/National Institutes of Health National
Institute of Environmental Health Sciences
National Center for Toxicogenomics (NCT;
Waters et al. 2003; http://www.niehs.nih.gov/
nct/), and the U.S. FDA NCT (Tong et al.
2003; http://www.fda.gov/nctr/science/centers/
toxicoinformatics/index.htm) have worked
closely together. The respective databases are
based on the international standards developed
by the MGED Society (Brazma et al. 2001;
Spellman et al. 2002). After the very favorable
response that the MIAME received from the
microarray community and key scientiﬁc jour-
nals (Ball et al. 2002, 2004; Nature 2002), the
MIAME checklist was extended to describe
array-based toxicogenomics experiments. The
MIAME-Tox checklist (MGED 2004) is an
attempt to deﬁne the minimum information
required to interpret unambiguously and
potentially reproduce and verify array-based
toxicogenomics experiments. MIAME-Tox also
supports a number of other objectives, for
example, linking data from different experi-
mental domains within a study and linking
several studies from one institution and
exchanging toxicogenomics data sets among
public databases. The major objective of
MIAME-Tox is to guide development of
toxicogenomics databases and data manage-
ment software. Without a sufﬁcient depth of
data in these resources, the scientiﬁc commu-
nity’s opportunity to develop consensus on
analysis and application of these data for risk
assessment or screening may be limited. The
availability of this level of information regard-
ing platform specification, appropriate com-
mon reference standards, and the toxicologic
study alone will facilitate the predictive value of
toxicogenomics across different array-based
platforms. This, in turn, will result in a greater
appreciation of and conﬁdence in the value of
toxicogenomics within a regulatory context,
such that testing strategies can be optimized,
predictive alternative models can be identiﬁed,
and animal use can be reduced (Supplemental
Material, Section 2; http://ehp.niehs.nih.gov/
members/2005/8247/suppl.pdf).
Moreover, the long-term provision of a
MIAME-Tox–compliant database with a
MAGE-ML (Microarray Gene Expression
Markup Language) export is required for the
long-term storage of toxicogenomics data. This
would directly support the role of ECVAM,
ICCVAM/NICEATM, and other validation
bodies in the validation of toxicogenomics-
based test methods.
The recommendations related to the tech-
nical and bioinformatics aspects of validation




Regulatory scientists are increasingly being
called upon to consider incorporation of toxi-
cogenomics data in regulatory assessment
processes that involve evaluation of potential
human health or environmental hazard and
risk. Those scientists will need to be able to
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in vivo and in vitro toxicogenomics-based test
methods and the resulting data that might be
submitted in support of regulatory decision
making. Whether a method has been deter-
mined to be valid for a speciﬁc purpose will be
an important factor for the consideration of its
use for regulatory purposes. Furthermore, the
level of confidence held by regulators will
influence regulatory acceptance of methods
and data, and will affect both the further pur-
suit of toxicogenomics technologies and tech-
nologic improvements and the extent of
industry application of these technologies.
Potential uses of toxicogenomics data in the
regulatory area. The potential of toxico-
genomics-based methods in contributing to
regulatory assessment processes is broad.
Examples might include, but would not be
limited to, obtaining microarray data from
individual in vivo bioassays or in vitro cell or
tissue-based assays or from batteries of assays,
using conventional or high-throughput
approaches. In accordance with the current
developing state of the science, realistic possi-
bilities for initial uses of toxicogenomics data
in regulatory settings might be first in the
realm of hazard assessment, such as to support
chemical mechanism of action arguments.
Other early uses might include aiding individ-
ual chemical/chemical mixture screening or
ranking exercises to set priorities for toxicity
testing or to sort chemicals into batches. These
types of applications might involve identiﬁca-
tion of individual genes or gene patterns associ-
ated with particular toxic effects or pathways,
adaptive responses, or metabolic pathways.
However, global pattern recognition–type
techniques are, as yet, not considered to be
ready to fully replace traditional bioanalytical
methods for predicting toxicity or elucidating
information on mechanism of action or bio-
chemical pathway component identiﬁcation.
Using only human or animal in vitro or
in vivo data derived from toxicogenomics
technology to estimate such parameters as
adverse/no adverse effect levels or to determine
dose–response relationships for conducting
risk assessments is regarded as a much longer
term goal. However, for hazard assessment
purposes, the possibility of considering toxi-
cogenomics data along with other types of
toxicologic information and data [e.g., from
in vivo and in vitro studies, determinations of
quantitative structure–activity relationships
(QSAR) or SAR] in a weight-of-evidence
approach on a case-by-case basis was not dis-
counted. Regulatory bodies have begun to
craft preliminary proposals, policies, and guid-
ance for the submission and use of omics-type
data in regulatory deliberations and to provide
encouragement for the use and further devel-
opment of the technology (U.S. EPA 2002;
U.S. FDA 2005). Additionally, organizations
such as the OECD are actively working with
member countries on approaches that seek to
harmonize the use of omics-derived informa-
tion for hazard assessment related to health
and environmental effects.
Harmonization of toxicogenomics-based
test methods will ﬁrst necessitate the standard-
ization and validation of the speciﬁc test proto-
col(s) developed for a specific purpose(s), as
conducted by international validation bodies
such as ECVAM and ICCVAM/NICEATM.
It will then be important for such organiza-
tions to interface with the OECD to ensure
the appropriate crafting of harmonized OECD
toxicogenomics-based test guidelines that are
based upon standardized, adequately validated
procedures, that are considered practical, and
that permit consistent regulatory judgments.
Case for a modular approach to validation.
Because of the extraordinary rate at which
toxicogenomics technologies are evolving, cur-
rent validation processes might need to adapt so
as to accommodate the rapidly developing
changes and advancements while still observing
the basic tried-and-true validation principles.
To meet this anticipated need, a modular
approach to validation (Hartung et al. 2004)
was considered, not to abridge the process but
to allow for more ﬂexibility in data collection
and evaluation throughout the progressive
changes that the technology will undergo.
Typically, in the conventional validation proce-
dures for an alternative test method, a sequen-
tial approach to the process is taken. The test
protocol is ﬁrst optimized and its transferability
is determined. The resulting standardized
method is then evaluated for within-lab and
between-lab reproducibility and for its accu-
racy. Thus, an optimized, standardized protocol
linked to speciﬁc test method elements and a
prediction of outcome for given classes of
chemicals are evaluated together for perfor-
mance characteristics and applicability. Such a
linear validation model, although effectively
employed for other test methods, might not be
optimal for dynamic test methods in which
changes are rapidly introduced that improve or
alter the protocol or the technology incorpo-
rated in the protocol in any substantive way.
The linear validation model might result in
unnecessary delays in incorporating innovations
into toxicogenomics-type test methods. In con-
trast, with a modular approach to validation,
which capitalizes on the fundamental classic
concepts of validation as deﬁned by ECVAM
and ICCVAM (Balls et al. 1995; ICCVAM
1997, 2003), the different steps in the valida-
tion process are subdivided into independent
modules, each of which can be assessed individ-
ually so that those components that have been
completed need not undergo repeated valida-
tion. Further validation activities would instead
be directed to only that part of the process ﬂow
where needed. The proposed model would
accommodate validation of innovation affecting
only a particular part of the sequence such that
incorporation of advancements in a particular
sector into testing strategies would less likely 
be impeded. At the same time, a modular
approach to validation could efﬁciently handle
information/data gaps that could be ﬁlled over
time without derailing the validation stages
already achieved. The modular approach, com-
plemented with the use of performance stan-
dards (see “Validation as a Result of Procedural
Changes” above), is expected to facilitate and
help expedite the validation of the toxico-
genomics technology and test methods that are
based on toxicogenomics.
The modular approach follows the funda-
mental classic concepts of validation as deﬁned
by ECVAM and ICCVAM. Validation is
deﬁned as the process by which the relevance
and reliability of a test method for a specific
purpose are determined (Balls et al. 1995;
ICCVAM 1997, 2003). Adequate validation
Corvi et al.
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Table 2. Recommendations: focus on technology.
• Validation and QA/QC should be mandatory during the manufacturing of the arrays
• The array should undergo sequence veriﬁcation and sequences should be available in the public domain
• MIAME guidelines should be adhered to
• Initially, develop “best practices” for toxicogenomics, including the interpretation of data and how to manage 
uncertainties and limitations
• Subsequently develop guidance for and adherence to GLPs for toxicogenomics experiments
• Common reference standards should be considered
• A workshop should be convened to address the development of standards for RNA sample preparation (and other
biologic aspects of microarray analyses)
• Develop a “common” RNA standard including developing consensus about sources and maintenance of baseline
data for regulatory and research purposes
• Studies should be MIAME-Tox compliant
• Performance standards should be developed and implemented to evaluate reliability and accuracy of test methods
incorporating procedural modiﬁcations
• An ongoing dialogue should be maintained between scientists in the various relevant disciplines, including 
bioinformaticians, through meetings, published papers, and advisory/discussion panels (e.g., ILSI-HESI committee,
NCT consortium, OECD panel)
• Ensure that validation efforts and QA/QC criteria are not restrictive to the technology or its advancement
• Explore whether toxicogenomics measurements can deﬁne toxicologic effects quantitatively
• Develop prediction models (e.g., algorithms) for toxicogenomics-based test methods
• Develop a data infrastructure for capturing, storing, and reporting toxicogenomics data
• Ensure continuation of ﬁnancial support for long-term public database maintenanceinvolves development of a standardized test
method protocol and assessment of the proto-
col’s within- and between-laboratory variabil-
ity, predictive capacity/accuracy, usefulness and
limitations, and adherence to performance
standards.
Standards for comparison. As technologic
advancements are made and new, modiﬁed, or
revised toxicogenomics-type test methods are
put forward for consideration, it will be neces-
sary to have a means by which the performance
of proposed methodologies can be compared
with that of existing (traditional and nontradi-
tional) methods, especially those that employ
animals. The lack of an approach rooted ﬁrmly
in high-quality science could jeopardize
attempts to seek or gain regulatory acceptance
of toxicogenomics-based test methods and
strategies. Evaluations of test method perfor-
mance might be based on comparisons made
between particular parameters, as dictated by
the specific intent for which the assay was
developed. Examples include the following:
• In vivo–in vivo study comparisons to examine
concordance of gene changes with such fac-
tors as onset, duration, severity, dose, age,
possible temporal changes of effects, and
species differences
• In vitro–in vivo study comparisons to explore
gene changes associated with a critical event
or end point in an in vitro cell-based assay and
an established in vivo biomarker of toxicity
• In vitro–in vitro study comparisons to analyze
the responses of human and animal cell sys-
tems to xenobiotics
• Technologic comparisons to evaluate the
effects of proposed technical improvements
(e.g., comparing gene changes using different
techniques of array/platform preparation)
Accordingly, to detemine the appropriate
types of validation activity and comparison in a
given situation, it is important that the speciﬁc
purpose of the proposed methodology and a
detailed description of all relevant procedures
be clearly elaborated (Balls et al. 1995;
Hartung et al. 2004; ICCVAM 1997, 2003).
Toxicogenomics data from in vitro systems
and data relevance. At the present time,
toxicogenomics data derived from in vitro sys-
tems have been considered to have limited util-
ity in regulatory applications. However, a great
deal of interest exists for the further develop-
ment of in vitro–based toxicogenomics meth-
ods, for an examination of their potential
applicability in the regulatory arena, and for an
appraisal of their potential for contributing to
improvements in animal welfare. It is antici-
pated that technologic advancements will ulti-
mately facilitate the use of in vitro–based
methods as adjuncts to or surrogates for
in vivo–based methods. Possible areas where
validated in vitro–based toxicogenomics test
methods might play a future role include
a) preliminary assessments (prescreens),
b) complementary testing that might assist in
obtaining additional (e.g., mechanistic) infor-
mation, and c) surrogate tests that could help
in the reﬁnement, reduction, and replacement
of animals used for omics-based or traditional
testing methods. One exciting aspect of toxico-
genomics technology is the prospect of being
able to identify species differences and/or
similarities in the response to a xenobiotic.
Although this is not viewed as near-term
prospect, it obviously has potential applications
for hazard and risk assessment purposes and
could also have an impact on previous regula-
tory decisions when the technology becomes
sufﬁciently advanced to permit such uses for it.
Additional regulatory acceptance issues. In
considering approaches to validation, achieving
regulatory acceptance of toxicogenomics-based
methods or acceptance of information/data
derived from such methods is an important
goal. Regulators will be asked to evaluate
whether data submitted using omics technolo-
gies can be used in support of a particular or
broader based toxicologic, pharmacologic, or
physiologic premise. For example, experiments
using microarrays demonstrated increased
expression of a cluster of related genes that was
associated with enhanced activity and produc-
tion of a microsomal enzyme important in the
metabolic activation of a chemical to a toxic
entity, which in turn was associated with a
histopathologic biomarker lesion in the liver
with a known human cancer correlate. Each of
the events in this example can be thought of 
as a sequence of separate critical steps or
information levels (Figure 2) that progressively
connect omics data (from microarrays) to gene
expression changes (increased expression), to a
biochemical pathway (liver enzyme induction
leading to toxic metabolite formation), to a
toxicologic effect in vivo (liver lesion) with
human relevance (cancer). Moving between
two levels involves a prediction of outcome
linking both steps. At each of these prediction
junctures, regulators would be looking for evi-
dence to scientiﬁcally substantiate moving to
the next step and whether  the prediction link-
ing the levels (e.g., in this example, prediction
1, 2, 3, or 4 in Figure 2) was adequately vali-
dated. Theoretically, with this type of system,
validated links could be established between
any two levels. Technologic advancements or
new information could be independently
incorporated into a given level and considered
and evaluated for the speciﬁc relevant predic-
tion juncture. In this way, each of the predic-
tion levels can be assessed independently and
the validity of the links determined.
In the future toxicogenomics-based test
methods may be shown to have been ade-
quately validated and technically suitable for
certain specific purposes, but regulatory
acceptability and implementation will depend
partly on whether the methods validated can
be used for a given regulatory agency or pro-
gram, that is, they are applicable to the prod-
ucts that fall within their regulatory purview.
Some regulatory bodies may have internal
peer-review processes, speciﬁc regulatory man-
dates, and/or regulatory assessment procedures
that also have a role in the determination of
test method applicability in regulatory pro-
grams, even though a test method may have
been appropriately validated.
The widespread use of omics technologies
will also bring about increasing demands on the
regulatory community in terms of training of
regulatory personnel in areas such as potential
applications; data QC, analysis, and interpreta-
tion; statistical analysis; limitations of the tech-
nology; and how the information might be
incorporated into safety, hazard, and risk assess-
ment processes. To satisfy these needs, regula-
tory agencies have been engaging in developing
and implementing training procedures, hiring
scientists with the necessary technical knowl-
edge and experience, establishing centers of
excellence and dedicated laboratories focused
specifically on the various omics and related
informatics areas [e.g., National Center for
Toxicological Research (U.S. FDA), NCT
(NIEHS), Minister of Health Labour and
Welfare–National Institute of Health Sciences
Project in Japan, Netherlands Genomics
Initiative, and EMBL–EBI, where informatic
scientists are working with experimental
practictioners and the MGED Society to ensure
that transcriptomic experiments can be mapped
on to regulatory toxicology studies]. In addition
the regulatory arena has found that mainte-
nance of open lines of communication with
appropriate external scientists facilitates cooper-
ation and the sharing of technical aspects, skills,
Validation of toxicogenomics-based test systems
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Figure 2. Process flow showing different indepen-
dent prediction levels considered important in
assessing validity of a toxicogenomics-based test
method.









Prediction 4and practical experiences that help to broaden
the collective knowledge base. Regardless, as the
technology evolves further and finds wider
application and acceptance, it will be necessary
to address such fundamental matters as a) the
generation, management, and interpretation of
massive amounts of data; b) the consequent
complex questions that will undoubtedly arise
(e.g., what constitutes an adverse effect as
identified using the technology; how does a
given gene pattern correlate with a particular
toxic end point or relate to onset, duration, and
severity of effects, and to age, dose, and
species?); and c) the limitations to the technol-
ogy. Addressing such issues efﬁciently will war-
rant an ongoing dialogue between regulators
and practitioners and a willingness to share rele-
vant experiential and theoretical knowledge.
Standard submission and presentation formats
compatible with electronic data submission
likely would need to be developed. Programs
and staff would need to learn how information
from the new technologies might be incorpo-
rated in regulatory practices and decision-
making processes and would also have to face
possible incongruities between toxicogenomics-
derived data and existing or future submissions
of conventional toxicity data. A number of
regulatory authorities have already begun to
contemplate and make provisions for this enor-
mous and challenging task, but others may not
yet have committed the resources to do so.
The recommendations related to regulatory
acceptance and use of toxicogenomics-based
test methods are listed in Table 3.
Conclusions
This workshop was organized as a result of the
rapid growth and technologic advancements in
the field of toxicogenomics; the promise it
offers for numerous scientiﬁc arenas, especially
human health and the environment; and the
interest demonstrated by regulatory agencies as
well as by the industrial sector. Consequently, it
has become apparent that a considerable effort
needs to be invested in the appropriate valida-
tion of both the technology alone and those test
methods that incorporate the technology. The
workshop provided a platform for technical
experts in the ﬁeld to become cognizant of the
validation principles and regulatory issues to be
encountered and for regulators and principal
validation bodies to gain a better sense of those
technologic aspects that would lend themselves
to standardization, harmonization, and valida-
tion. Thus, this workshop was an important
initiative that fostered an exchange of informa-
tion fundamental to the ultimate adoption of
toxicogenomics-based test methods for regula-
tory decision-making purposes. It is envisioned
that the conclusions and recommendations that
resulted will be a basis for future validation con-
siderations for test method applications of
toxicogenomics technologies in the regulatory
arena and evaluating their potential utility for
hazard/safety/risk assessments.
Several aspects of the validation of toxico-
genomics that were identiﬁed as needing fur-
ther exploration to help facilitate regulatory
acceptance of future toxicogenomics-based test
methods are as follows:
•Conduct toxicogenomics-based tests and the
associated conventional toxicologic tests in
parallel to a) generate comparative data sup-
portive of the use of the former in place of
the latter or b) provide relevant mechanistic
data to help deﬁne the biological relevance of
such responses within a toxicologic context
• Determine and understand the range of 
biologic and technical variability between
experiments and between laboratories and
ways to bring about greater reproducibility
• In the short term, favor deﬁned biomarkers
that are independent from technology plat-
forms, and therefore are easier to validate; in
the longer term, focus on pathway analysis
(i.e., system biology approach) rather than
just on individual genes
• Harmonize reference materials, QC mea-
sures, and data standards and develop com-
patible databases and informatics platforms
that are key components of any validation
strategy for a toxicologic method; this can
only be achieved by promoting partnerships
and collaborations among ongoing initia-
tives in toxicogenomics, standardization,
and validation
•Determine performance standards for
toxicogenomics-based test methods that will
serve as the yardsticks for comparable test
methods that are based on similar opera-
tional properties
•Define further the modular validation
scheme that would allow keeping up with
methodologic improvements and innovations
without having to repeat the entire validation
process but would, however, integrate
ECVAM and ICCVAM principles of valida-
tion and acceptance.
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